What analysts say:
- Buy, sell, or hold?: Analysts think investors should stand pat on CryoLife with two of three analysts rating it hold. Analysts don't like CryoLife as much as competitor Vascular Solutions overall. Six out of seven analysts rate Vascular Solutions a buy compared to one of three for CryoLife. That rating hasn't budged in three months as analysts have remained steadfast in their opinion of the stock.
- Revenue forecasts: On average, analysts predict $31.1 million in revenue this quarter. That would represent a rise of 6.5% from the year-ago quarter.
- Wall Street earnings expectations: The average analyst estimate is earnings of $0.06 per share. Estimates range from $0.06 to $0.07.
What our community says:
CAPS All-Stars are enthusiastically backing the stock, with 98.4% assigning it an outperform rating. The greater community concurs with the All-Stars, as 97.1% give it a rating of outperform. Fools have embraced CryoLife and haven't been shy with their opinions lately, logging 125 posts in the past 30 days. Even with a robust four out of five stars, CryoLife's CAPS rating falls a little short of the community's upbeat outlook.
Management:Now let's look at how efficient management is at running the business. Margins illustrate how efficiently a company captures portions of sales dollars. The company's operating margins increased year-over-year in the past two quarters. Operating margins reflect the total sales revenue that the company retains after costs. Here are CryoLife's reported margins for the last four quarters:
One final thing: If you want to keep tabs on CryoLife movements, and for more analysis on the company, make sure you add it to your watchlist.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.Earnings estimates provided by Zacks.